Bicara Therapeutics (BCAX) EBT (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of EBT data on file, last reported at -$56.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 52.71% year-over-year to -$56.2 million; the trailing twelve-month figure through Mar 2026 stood at -$157.1 million (down 70.64% YoY), and the FY2025 full-year result was -$137.7 million, down 103.12% from the prior year.
• EBT for Q1 2026 stood at -$56.2 million, down from -$37.3 million in the prior quarter.
• Across five years, EBT topped out at -$12.4 million in Q4 2023 and bottomed at -$56.2 million in Q1 2026.
• The 4-year median for EBT is -$22.8 million (2023), against an average of -$27.0 million.
• The widest annual swing landed in 2024, when EBT increased 23.48%; it then plunged 194.03% in 2025.
• A 4-year view of EBT shows it stood at -$12.4 million in 2023, then tumbled by 67.04% to -$20.8 million in 2024, then slumped by 79.74% to -$37.3 million in 2025, then slumped by 50.43% to -$56.2 million in 2026.
• The last three EBT figures came in at -$56.2 million (Q1 2026), -$37.3 million (Q4 2025), and -$36.3 million (Q3 2025), per Business Quant data.

Peer Comparison